Contemporary Issues on Antinuclear Antibody Nomenclature
Detection of ANA by IFA technique demonstrates binding to specific intracellular structures within the cells resulting in a number of staining patterns that are usually categorized based on the subcomponents recognized and degree of binding reflected by the fluorescent intensity or titer. The provision of ANA pattern and titer is considered to be of added clinical value especially with respect to other methods for their detection [1-3, 15, 21-29]. As mentioned above, the most commonly recognized and reported patterns by clinical laboratories are those staining the nuclear region referred to as homogeneous, speckled, centromere, and nucleolar [1, 2, 15-17]. With the use of HEp-2 cells
…show more content…
Despite the recognition that non-nuclear patterns, cytoplasmic and mitotic are clinically relevant, no consensus to report these as ANA negative or positive was reached. Central to this contention were the implications for existing diagnostic/classification criteria for ANA-associated diseases such as autoimmune hepatitis [16, 31].
Assessment of Antinuclear Antibodies
Since the adoption of ANA as a routine clinical laboratory test, the techniques for their detection and/or measurement have evolved and now encompass a variety of immunological methods [21-30]. IFA using HEp-2 cells is considered the gold standard method for detecting ANA with a number of cons and pros [1-4, 21, 22, 26, 30]. Central to the analytical challenges associated with ANA IFA testing are its labor-intensiveness with significant amount of training required for competence, subjectivity in titer, poor standardization of reagents, and pattern determination, labor-intensiveness as well as a decline workforce in the clinical laboratory [1,-4, 15, 30, 32]. Thus, in some laboratories, ANA IFA has been replaced by high throughput, less subjective methods including ELISA and multiplex assays such as the line immunoassays (LIA) and multiplexed bead assays (MBA) [22-29]. The non-IFA assays differ in source, purity, concentration and binding capacity of the antigens; reference materials or standards used in their development, as well as secondary antibodies (conjugates) detection. Therefore, it is not
The problem of possible contamination of other long-term cultured tumor cell lines with HeLa cells not only caused an international embarrassment, but also raised the concern of misattributing a specific property so another cell line, for example, a virus or a tumor-specific marker, which actually belongs to HeLa. With the continued and growing use of tissue culture in biochemist research, intra- and interspecific contamination becomes a significant risk. The determination of stable genetic markers on cultured cells is a powerful tool for monitoring such contamination. Recent experiments in which cultured cells and innumerable clones of somatic cell hybrids have been used for genetic analysis have shown that, with the proper use of polymorphic markers to characterize the cells, the possibility of undetected cross contamination of cultures is no longer the problem it once may have
ELISA stands for enzyme-linked immunoassay. It is a commonly used laboratory test to detect antibodies in the blood. An ELISA or enzyme-linked immunosorbent assay is a method used in the laboratory to aid in the diagnosis of a wide range of diseases. This test is performed on blood or urine and is used for measuring the amount of a particular protein or substance in these bodily fluids, such as infectious agents, allergens, hormones or drugs. This test relies on the interaction
To test the blood, we first dropped two drops of blood into two spots in a micro-well plate, then we added the appropriate serum to both and mixed with a small stick. One side was labeled A, for the A Anti-Serum, and one was labeled B. If the A blood clotted it meant that the A antigen was found, and likewise with B. If both clotted the blood type was AB, and if neither clotted the blood was type O. Some errors made
The cells were washed with PBS and then incubated in serum-free media and treated with 2.5 μM of free sorafenib or an equivalent sorafenib concentration of SMA-Sor, 3 μM of free nilotinib or an equivalent nilotinib concentration of SMA-Nilo, DMSO or SMA for 48 h. Following treatment, media was collected, centrifuged to remove cell debris, and freeze-dried for 12 h. Samples were rehydrated and mixed with loading buffer (0.4 M Tris, pH 6.8, 5% SDS, 20% glycerol, 0.03% bromophenol blue). For zymography, samples were loaded on a 10% SDS-polyacrylamide gel containing 1 mg/mL of gelatin. After electrophoresis, the gels were incubated in renaturing solution (2.5% Triton-X-100 (w/v)) for 30 min at room temperature and then for 24 h at 37°C in a developing buffer containing 50 mM Tris, pH 7.5, 200 mM NaCl, 4 mM CaCl2, and 0.02% NP40. The gels were then stained with Coomassie blue R250, and regions without staining were indicative of gelatin lysis. The gels were briefly rinsed and scanned. For MMP-9 and isthmin-1 secretion, samples were loaded on a 10% SDS-polyacrylamide gel, and the expression of MMP-9 and isthmin-1 assessed by western blotting using anti-MMP-9 (D6O3H, Cell Signaling) and anti-isminth-1 antibodies (Biorbyt, San Francisco, CA,
An antibody known to be slgA, is usually found in the mucosa and digestive system and with its rise and fall, helps to ascertain the immunity power of allergic reaction. Patient’s test result of blood or stool, which is usually done who suffers chronic digestion ailments, indicates presence of antibodies, however it is detection of allergies is more accurate in the blood tests than in stool tests. To know more go through ”Laboratory Testing for Candida Yeast Infections”,where you will have more insight to the ELISA blood test for the IgG/IgA antibody levels and the CDSA x 3 stool tests.
This was completed with over 65 tissue samples from various locations. The analysis was performed with quantitative PCR, using fluorescent signals.
Positive ANA titer (1:1280); elevated antibodies against double-stranded DNA; low C3 level (73 mg/dl); all else (platelets, direct/indirect Coombs tests/anti-phosopholipid Abs) normal.
The methods of obtaining the cancerous epithelial samples from various areas was a clear way of observing both the level of amplification of CCND1 and the presence of cancer within those tumors or samples. The FISH technique was fitting to localize the specific DNA sequences related to the cause and effect of amplification. Epithelial tissues which contained some development of cancer cells were studied. The researchers used samples that were stored at the University Medical Center Hamburg-Eppendorf, making sure to used samples from areas distant from one another (Burandt, et. al). Taking samples from various areas helped to further see the effect of various amount of amplification of the protein and how it affected the epithelial tissues at different stages.
The first experiment we ran was the α-smooth muscle actin (asma) stain. The purpose of this stain was to use a primary and secondary antibody to indirectly stain the microfilaments that characterize myofibroblasts. Under a fluorescent microscope, this will provide a visual representation of how many fibroblasts in our samples had differentiated into myofibroblasts. To set up for this experiment, fibroblasts were plated on coverslips and incubated for seven days, to reach 100% confluency, in either the presence or absence of allopurinol. After one week the coverslips were fixed with methanol and the first antibody, a mouse anti-human asma, was applied onto the coverslip and kept refrigerated overnight. The next day the coverslips were rinsed with PBS, all rinses are performed with PBS, and the second antibody, a goat anti-mouse rhodamine, was applied to the coverslips for thirty minutes in a dark place. Lastly, after another rinse, a DAPI counterstain, which would interact with the DNA in the nucleus of every fibroblast to make them visible, was applied for fifteen minutes and rinsed. Then the coverslips were mounted onto slides with glycerol and looked at under the fluorescent microscope. The nuclei of all of the cells lit up blue and the microfilaments in the differentiated fibroblasts, myofibroblasts, lit up bright
diH20 acted as a negative control in the experiment, all cells, both in intrafollicular zone and in interfollicular zone stained purple. Cells stained brown in the negative control indicate non-specific staining.
15 cell lines were acquired for the purpose of this experiment. Process of subcellular compartment fractionation was performed on these cell lines, this included complete cells, nucleus and cytosol (seen in
The test uses immunofluorescent antinuclear antibodies to check for nuclei of a patient's cells [68]. A blood serum sample is taken from the patient and placed on a slide with specific cells that can be from a rodent or other human tissue cell lines[68]. If antinuclear antibodies are present, then the serum will interact with the cells and when a secondary antibody is added, it will fluoresce [68]. 98% of SLE patient present with positive ANA tests but it is also seen in 5-10% of people without SLE [68]. Other antibodies such as anti-double stranded DNA (anti-dsDNA), anti-Smith (anti-Sm), anti-U1RNP, anti-histone, anti-Ro/SSA and anti-La/SSB are generally checked after a positive confirmation from the antinuclear test [68]. Less than 1% of individuals have anti-dsDNA antibodies, compared to 30% of in people with SLE[68]. Anti-Sm antibodies are rarely found in healthy individuals and is present in about 20% of patients with SLE [68]. Anti-U1RNP antibodies are usually found with anti-Sm antibodies, and close to 25% of SLE patients are seen with this antibody [68]. Anti-histone, anti-Ro/SSA and anti-La/SSB antibodies are not specifically linked to SLE but are usually found in SLE patients
There is not a Food and Drug Administration (FDA) licensed test available, but the Centers for Disease Control and Prevention (CDC) has released a document to guide PCR assays. Commercial serologic tests are possible, but no kit is yet licensed by the FDA, nor have cutoff point for diagnostic values of immunoglobulin (Ig) G antibody been established by the FDA. Each test has a different “window” of efficiency, and various sensitivities to factors like immunization, previous infection, and antimicrobial
Cytogenic analysis – Microscopic examination of lymphocytes to look for structural changes or changes in number of chromosomes.
The recognition of a well-defined ANA staining pattern using the HEp-2 cell substrate may be helpful in